会员体验
专利管家(专利管理)
工作空间(专利管理)
风险监控(情报监控)
数据分析(专利分析)
侵权分析(诉讼无效)
联系我们
交流群
官方交流:
QQ群: 891211   
微信请扫码    >>>
现在联系顾问~
热词
    • 1. 发明授权
    • 1-(2H)-isoquinolone derivative
    • 1-(2H) - 异喹诺酮衍生物
    • US08143274B2
    • 2012-03-27
    • US10588611
    • 2005-02-07
    • Kazuo HattoriSatoshi NiizumaTakehiro OkadaHiroyuki EdaKenji TatsunoMiyuki Yoshida
    • Kazuo HattoriSatoshi NiizumaTakehiro OkadaHiroyuki EdaKenji TatsunoMiyuki Yoshida
    • C07D217/24A61K31/47
    • C07D217/24
    • The present invention provides: a compound represented by the following formula (I): [wherein Y1 and Y4 represent a hydrogen atom or a halogen atom; either one of Y2 and Y3 represents —NR1R2, and the other represents a hydrogen atom or a halogen atom; X represents an aryl group or a heteroaryl group that may be substituted; R1 represents a hydrogen atom, or a C1-8 alkyl group that may be substituted; and R2 represents a C1-8 alkyl group that is substituted with one or more substituents, —COOR3, —COR4, —COSR5, —CONR6R7, —NR22R23, or —C═NR24R25; or R1 and R2, together with a nitrogen atom to which they are bonded, may form a 4- to 10-membered hetero ring containing at least one nitrogen atom (wherein the hetero ring may be substituted with one or more substituents selected from Group C)], a prodrug thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical, a pharmaceutical composition, or the like, which comprises the compound.
    • 本发明提供:由下式(I)表示的化合物:[其中Y 1和Y 4表示氢原子或卤素原子; Y2和Y3中的任一个表示-NR1R2,另一个表示氢原子或卤素原子; X表示可被取代的芳基或杂芳基; R1表示氢原子或可被取代的C1-8烷基; 并且R 2表示被一个或多个取代基-COOR 3,-COR 4,-COSR 5,-CONR 6 R 7,-NR 22 R 23或-C≡NR24 R 25取代的C 1-8烷基; 或R 1和R 2与它们所键合的氮原子一起可以形成含有至少一个氮原子的4至10元杂环(其中杂环可以被一个或多个选自C组的取代基取代 )],其前药,或其药学上可接受的盐; 以及包含该化合物的药物,药物组合物等。
    • 2. 发明申请
    • 1-(2H)-isoquinolone derivative
    • 1-(2H) - 异喹诺酮衍生物
    • US20070185160A1
    • 2007-08-09
    • US10588611
    • 2005-02-07
    • Kazuo HattoriSatoshi NiizumaTakehiro OkadaHiroyuki EdaKenji TatsunoMiyuki Yoshida
    • Kazuo HattoriSatoshi NiizumaTakehiro OkadaHiroyuki EdaKenji TatsunoMiyuki Yoshida
    • A61K31/47C07D217/24C07D401/02
    • C07D217/24
    • The present invention provides: a compound represented by the following formula (I): [wherein Y1 and Y4 represent a hydrogen atom or a halogen atom; either one of Y2 and Y3 represents —NR1R2, and the other represents a hydrogen atom or a halogen atom; X represents an aryl group or a heteroaryl group that may be substituted; R1 represents a hydrogen atom, or a C1-8 alkyl group that may be substituted; and R2 represents a C1-8 alkyl group that is substituted with one or more substituents, —COOR3, —COR4, —COSR5, —CONR6R7, —NR22R23, or —C═NR24R25; or R1 and R2, together with a nitrogen atom to which they are bonded, may form a 4- to 10-membered hetero ring containing at least one nitrogen atom (wherein the hetero ring may be substituted with one or more substituents selected from Group C)], a prodrug thereof, or a pharmaceutically acceptable salt thereof; and a pharmaceutical, a pharmaceutical composition, or the like, which comprises the compound.
    • 本发明提供:由下式(I)表示的化合物:[其中Y 1和Y 4表示氢原子或卤素原子; Y 2和Y 3中的任一个表示-NR 1 R 2 O 2,另一个表示氢原子 或卤素原子; X表示可被取代的芳基或杂芳基; R 1表示可以被取代的氢原子或C 1-8烷基; 和R 2表示被一个或多个取代基取代的C 1-8烷基,-COOR 3,-COR 2, 4,-COSR 5,-CONR 6,R 7,-NR 22 R SUP > 23 或-C-NR 24 R 25; 或R 1和R 2与它们所键合的氮原子一起可以形成含有至少一个氮原子的4至10元杂环( 其中所述杂环可以被一个或多个选自组C)的取代基取代,其前药或其药学上可接受的盐; 以及包含该化合物的药物,药物组合物等。